Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Postmenopausal Vaginal Atrophy Drugs market report explains the definition, types, applications, major countries, and major players of the Postmenopausal Vaginal Atrophy Drugs market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Actavis plc
Allergan plc
Teva Pharmaceuticals Ltd
Bionovo Inc
Pfizer Inc
Shionogi & Company
Endoceutics Inc
Therapeutics MD Inc
Novo Nordisk A/S
Shionogi & Co Ltd
By Type:
Premarin
Vagifem
Estrace
Estring
Femring
By End-User:
Vaginal Gels
Creams
Tablets
Rings
Patches
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Postmenopausal Vaginal Atrophy Drugs Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Postmenopausal Vaginal Atrophy Drugs Outlook to 2028- Original Forecasts
-
2.2 Postmenopausal Vaginal Atrophy Drugs Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Postmenopausal Vaginal Atrophy Drugs Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Postmenopausal Vaginal Atrophy Drugs Market- Recent Developments
-
6.1 Postmenopausal Vaginal Atrophy Drugs Market News and Developments
-
6.2 Postmenopausal Vaginal Atrophy Drugs Market Deals Landscape
7 Postmenopausal Vaginal Atrophy Drugs Raw Materials and Cost Structure Analysis
-
7.1 Postmenopausal Vaginal Atrophy Drugs Key Raw Materials
-
7.2 Postmenopausal Vaginal Atrophy Drugs Price Trend of Key Raw Materials
-
7.3 Postmenopausal Vaginal Atrophy Drugs Key Suppliers of Raw Materials
-
7.4 Postmenopausal Vaginal Atrophy Drugs Market Concentration Rate of Raw Materials
-
7.5 Postmenopausal Vaginal Atrophy Drugs Cost Structure Analysis
-
7.5.1 Postmenopausal Vaginal Atrophy Drugs Raw Materials Analysis
-
7.5.2 Postmenopausal Vaginal Atrophy Drugs Labor Cost Analysis
-
7.5.3 Postmenopausal Vaginal Atrophy Drugs Manufacturing Expenses Analysis
8 Global Postmenopausal Vaginal Atrophy Drugs Import and Export Analysis (Top 10 Countries)
-
8.1 Global Postmenopausal Vaginal Atrophy Drugs Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Postmenopausal Vaginal Atrophy Drugs Export by Region (Top 10 Countries) (2017-2028)
9 Global Postmenopausal Vaginal Atrophy Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Premarin Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Vagifem Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Estrace Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Estring Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Femring Consumption and Growth Rate (2017-2022)
-
9.2 Global Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Vaginal Gels Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Creams Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Tablets Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Rings Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Patches Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Postmenopausal Vaginal Atrophy Drugs Market Analysis and Outlook till 2022
-
10.1 Global Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.2.2 Canada Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.2.3 Mexico Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.3.2 UK Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.3.3 Spain Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.3.4 Belgium Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.3.5 France Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.3.6 Italy Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.3.7 Denmark Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.3.8 Finland Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.3.9 Norway Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.3.10 Sweden Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.3.11 Poland Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.3.12 Russia Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.3.13 Turkey Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.4.2 Japan Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.4.3 India Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.4.4 South Korea Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.4.5 Pakistan Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.4.6 Bangladesh Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.4.7 Indonesia Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.4.8 Thailand Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.4.9 Singapore Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.4.10 Malaysia Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.4.11 Philippines Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.4.12 Vietnam Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.5.2 Colombia Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.5.3 Chile Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.5.4 Argentina Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.5.5 Venezuela Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.5.6 Peru Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.5.7 Puerto Rico Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.5.8 Ecuador Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.6.2 Kuwait Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.6.3 Oman Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.6.4 Qatar Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.6.5 Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.6.6 United Arab Emirates Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.7.2 South Africa Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.7.3 Egypt Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.7.4 Algeria Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
-
10.8.2 New Zealand Postmenopausal Vaginal Atrophy Drugs Consumption (2017-2022)
11 Global Postmenopausal Vaginal Atrophy Drugs Competitive Analysis
-
11.1 Actavis plc
-
11.1.1 Actavis plc Company Details
-
11.1.2 Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Actavis plc Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Allergan plc
-
11.2.1 Allergan plc Company Details
-
11.2.2 Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Allergan plc Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
11.2.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Teva Pharmaceuticals Ltd
-
11.3.1 Teva Pharmaceuticals Ltd Company Details
-
11.3.2 Teva Pharmaceuticals Ltd Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Teva Pharmaceuticals Ltd Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
11.3.4 Teva Pharmaceuticals Ltd Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Bionovo Inc
-
11.4.1 Bionovo Inc Company Details
-
11.4.2 Bionovo Inc Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Bionovo Inc Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
11.4.4 Bionovo Inc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Pfizer Inc
-
11.5.1 Pfizer Inc Company Details
-
11.5.2 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
11.5.4 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Shionogi & Company
-
11.6.1 Shionogi & Company Company Details
-
11.6.2 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
11.6.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Endoceutics Inc
-
11.7.1 Endoceutics Inc Company Details
-
11.7.2 Endoceutics Inc Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Endoceutics Inc Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
11.7.4 Endoceutics Inc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Therapeutics MD Inc
-
11.8.1 Therapeutics MD Inc Company Details
-
11.8.2 Therapeutics MD Inc Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Therapeutics MD Inc Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
11.8.4 Therapeutics MD Inc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Novo Nordisk A/S
-
11.9.1 Novo Nordisk A/S Company Details
-
11.9.2 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
11.9.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Shionogi & Co Ltd
-
11.10.1 Shionogi & Co Ltd Company Details
-
11.10.2 Shionogi & Co Ltd Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Shionogi & Co Ltd Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
11.10.4 Shionogi & Co Ltd Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
11.10.5 Recent Research and Development Strategies
12 Global Postmenopausal Vaginal Atrophy Drugs Market Outlook by Types and Applications to 2028
-
12.1 Global Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Premarin Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Vagifem Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Estrace Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Estring Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Femring Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Vaginal Gels Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Creams Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Tablets Consumption Forecast and Growth Rate (2022-2028)
-
12.2.4 Global Rings Consumption Forecast and Growth Rate (2022-2028)
-
12.2.5 Global Patches Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Postmenopausal Vaginal Atrophy Drugs Market Analysis and Outlook to 2028
-
13.1 Global Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.2.2 Canada Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.2.3 Mexico Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.3.2 UK Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.3.3 Spain Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.3.4 Belgium Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.3.5 France Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.3.6 Italy Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.3.7 Denmark Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.3.8 Finland Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.3.9 Norway Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.3.10 Sweden Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.3.11 Poland Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.3.12 Russia Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.3.13 Turkey Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.4.2 Japan Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.4.3 India Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.4.4 South Korea Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.4.8 Thailand Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.4.9 Singapore Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.4.11 Philippines Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.5.2 Colombia Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.5.3 Chile Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.5.4 Argentina Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.5.6 Peru Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.6.3 Oman Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.6.4 Qatar Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.7.2 South Africa Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.7.3 Egypt Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.7.4 Algeria Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Postmenopausal Vaginal Atrophy Drugs
-
Figure of Postmenopausal Vaginal Atrophy Drugs Picture
-
Table Global Postmenopausal Vaginal Atrophy Drugs Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Postmenopausal Vaginal Atrophy Drugs Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Premarin Consumption and Growth Rate (2017-2022)
-
Figure Global Vagifem Consumption and Growth Rate (2017-2022)
-
Figure Global Estrace Consumption and Growth Rate (2017-2022)
-
Figure Global Estring Consumption and Growth Rate (2017-2022)
-
Figure Global Femring Consumption and Growth Rate (2017-2022)
-
Figure Global Vaginal Gels Consumption and Growth Rate (2017-2022)
-
Figure Global Creams Consumption and Growth Rate (2017-2022)
-
Figure Global Tablets Consumption and Growth Rate (2017-2022)
-
Figure Global Rings Consumption and Growth Rate (2017-2022)
-
Figure Global Patches Consumption and Growth Rate (2017-2022)
-
Figure Global Postmenopausal Vaginal Atrophy Drugs Consumption by Country (2017-2022)
-
Table North America Postmenopausal Vaginal Atrophy Drugs Consumption by Country (2017-2022)
-
Figure United States Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Canada Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Mexico Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Postmenopausal Vaginal Atrophy Drugs Consumption by Country (2017-2022)
-
Figure Germany Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure UK Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Spain Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Belgium Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure France Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Italy Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Denmark Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Finland Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Norway Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Sweden Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Poland Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Russia Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Turkey Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Table APAC Postmenopausal Vaginal Atrophy Drugs Consumption by Country (2017-2022)
-
Figure China Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Thailand Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Singapore Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Philippines Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Table South America Postmenopausal Vaginal Atrophy Drugs Consumption by Country (2017-2022)
-
Figure Brazil Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Colombia Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Chile Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Argentina Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Peru Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Table GCC Postmenopausal Vaginal Atrophy Drugs Consumption by Country (2017-2022)
-
Figure Bahrain Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Oman Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Qatar Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Table Africa Postmenopausal Vaginal Atrophy Drugs Consumption by Country (2017-2022)
-
Figure Nigeria Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Africa Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Egypt Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure Algeria Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Table Oceania Postmenopausal Vaginal Atrophy Drugs Consumption by Country (2017-2022)
-
Figure Australia Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Postmenopausal Vaginal Atrophy Drugs Consumption and Growth Rate (2017-2022)
-
Table Actavis plc Company Details
-
Table Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Actavis plc Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
Table Actavis plc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
Table Allergan plc Company Details
-
Table Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Allergan plc Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
Table Allergan plc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
Table Teva Pharmaceuticals Ltd Company Details
-
Table Teva Pharmaceuticals Ltd Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceuticals Ltd Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
Table Teva Pharmaceuticals Ltd Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
Table Bionovo Inc Company Details
-
Table Bionovo Inc Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bionovo Inc Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
Table Bionovo Inc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
Table Pfizer Inc Company Details
-
Table Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
Table Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
Table Shionogi & Company Company Details
-
Table Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
Table Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
Table Endoceutics Inc Company Details
-
Table Endoceutics Inc Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Endoceutics Inc Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
Table Endoceutics Inc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
Table Therapeutics MD Inc Company Details
-
Table Therapeutics MD Inc Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Therapeutics MD Inc Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
Table Therapeutics MD Inc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
Table Novo Nordisk A/S Company Details
-
Table Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
Table Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
Table Shionogi & Co Ltd Company Details
-
Table Shionogi & Co Ltd Postmenopausal Vaginal Atrophy Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Shionogi & Co Ltd Postmenopausal Vaginal Atrophy Drugs Main Business and Markets Served
-
Table Shionogi & Co Ltd Postmenopausal Vaginal Atrophy Drugs Product Portfolio
-
Figure Global Premarin Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Vagifem Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Estrace Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Estring Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Femring Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Vaginal Gels Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Creams Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Tablets Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Rings Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Patches Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Country (2022-2028)
-
Table North America Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Country (2022-2028)
-
Figure Germany Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Country (2022-2028)
-
Figure China Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Country (2022-2028)
-
Figure Brazil Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Country (2022-2028)
-
Figure Australia Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Postmenopausal Vaginal Atrophy Drugs Consumption Forecast and Growth Rate (2022-2028)
-
